News

A new funding deal will aid Saniona‘s development of Tesomet (tesofensine/metoprolol), a potential therapy to help control appetite and weight in people with Prader-Willi syndrome (PWS) and hypothalamic obesity, the company said. Saniona is planning to conduct a Phase 2b/3 trial, which the Denmark-based company…

Target enrollment of approximately 100 participants has been reached in a Phase 3 clinical trial evaluating the investigational oral therapy diazoxide choline controlled-release (DCCR) for reducing excessive appetite in people with Prader-Willi syndrome (PWS), Soleno Therapeutics has announced. Additional patients who are already scheduled to be screened…

Medix has submitted a new drug application to the Mexican food and drug administration — Comisión Federal para la Protección contra Riesgos Sanitarios, or COFEPRIS — seeking approval of tesofensine for the treatment of obesity. Tesofensine is one of two compounds that make up Tesomet, which Saniona…

Difficulties that people with Prader-Willi syndrome (PWS) have in adapting to their surroundings appear to be linked to psychiatric problems, generalized anxiety and hyperactivity, researchers report. Their study, “The Profiles and Correlates of Psychopathology in Adolescents and Adults with Williams, Fragile X and Prader-Willi Syndromes,” which also looked…

Despite low muscle tone, young adults with Prader-Willi syndrome can do exercises involving resistance training and likely will benefit from greater muscle strength, a study suggests. The research, “Myokine levels after resistance exercise in young adults with Prader–Willi syndrome (PWS),” was published in the American Journal of Medical…

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.